tirzepatide for cardiovascular disease outcomes trial results august 2025 compared with semaglutide and 10-year risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 Tirzepatide and the 10‐year predicted – Obesity and heart failure: what

In addition, GLP-1 can stimulate the epidermal growth factor (EGF), triggering the phosphatidylinositol-3 kinase (PI3K), which activates transcription factors associated with -cell growth while inhibiting those linked to -cell apoptosis (18)

: heartjnl-2025-327102

Mounjaro (tirzepatide) is a GLP-1 receptor agonist indicated for the treatment of type-2 diabetes and body weight management

Use a clean, fatty spot and rotate weekly

While genetics don't predict exact medication response, understanding your peptide genetic profile can support more informed conversations with your provider about whether compounded tirzepatide is the right fit and how closely to monitor early response

Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke